QGC001 is the first of a new class of drugs that can to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.
The First-in-Human clinical trial is a single ascending oral dose double-blind and placebo-controlled Phase I study proposed to evaluate the overall safety, tolerability and pharmacokinetics of QGC001 for treating hypertensive patients particularly those with Low Renin High Vasopressin profile (LRHV).
Quantum Genomics CEO Lionel Segard said the first study in human demonstrates the company’s ability to develop an innovative compound originated from academic research.
"QGC001 is the first representative of a new class of antihypertensive drugs that may improve the control of blood pressure in many patients with no current appropriate drug treatment and reduce their concomitant risks of cardiovascular diseases," Segard added.